Skip to Main Content

Paper Details

Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
J Immunol
2
2023
DC, Dendritic Cell, Dual-Epitope Dendritic Cell Vaccine, HER2, HER2 peptides, HER2-Expressing Breast Tumors, T cell, T cells, anti-, autologous DCs, breast cancer, dendritic cell, human epidermal growth factor 2, metastatic breast cancer, patient, patients, trastuzumab, vinorelbine
Author NameAffiliation
Benjamin G VincentUniversity of North Carolina
Benjamin G VincentLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Benjamin G VincentUNC School of Medicine
Benjamin G VincentUniversity of North Carolina at Chapel Hill
Jeffrey A FrelingerUNC School of Medicine
Joseph G IbrahimLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Joseph G IbrahimLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Carey K AndersLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Carey K AndersUniversity of North Carolina
Lisa A CareyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Lisa A CareyUniversity of North Carolina
Jonathan S SerodyUniversity of North Carolina
Jonathan S SerodyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Jonathan S SerodyUNC School of Medicine
Jonathan S SerodyUniversity of North Carolina at Chapel Hill
  • 1 - 15

Datasets

Release 1.2